Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 9;21(913):718-721.
doi: 10.53738/REVMED.2025.21.913.718.

[New developments in the prevention and management of RSV in 2025]

[Article in French]
Thomas Brahier  1 , Pierre Alex Crisinel  2 , Oriol Manuel  1 , Aline Munting  1
Affiliations

[New developments in the prevention and management of RSV in 2025]

[Article in French]
Thomas Brahier et al. Rev Med Suisse. .

Abstract
in English, French

Respiratory syncytial virus (RSV) causes respiratory infections, often mild but that can be severe for newborns, elderly individuals with comorbidities, and immunocompromised patients. In pediatrics, it is the leading cause of bronchiolitis and pneumonia, with numerous annual hospitalizations in Switzerland. Among the elderly, RSV leads to significant morbidity. Prevention has advanced with the introduction of vaccines such as Arexvy and Abrysvo, as well as nirsevimab for infants. These innovations are expected to significantly reduce the burden of RSV in the coming years.

Le virus respiratoire syncytial (VRS) cause des infections respiratoires souvent bénignes, mais graves pour les nouveau-nés, les personnes âgées avec des comorbidités et les patients immunodéprimés. En pédiatrie, il est la principale cause de bronchiolites et de pneumonies, avec de nombreuses hospitalisations annuelles en Suisse. Chez les personnes âgées, il provoque une forte morbidité. Des progrès significatifs en matière de prévention ont été réalisés avec l’introduction de vaccins tels qu’Arexvy et Abrysvo, ainsi que le nirsévimab pour les nourrissons. Ces innovations devraient réduire significativement le fardeau du VRS ces prochaines années.

PubMed Disclaimer

Conflict of interest statement

Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.

References

Publication types

MeSH terms

Substances

LinkOut - more resources